Updated on 2024/10/15

写真a

 
BABA Masanori
 
Organization
Research Field in Cooperation, Integrated Arts and Sciences Area Center for Advanced Science Research and Promotion Professor
Title
Professor

Degree

  • 医学博士 ( 1984.3   福島県立医科大学 )

Research Interests

  • HTLV-1

  • AIDS

  • Chemotherapy

  • SARS-CoV-2

  • Antiviral

Research Areas

  • Life Science / Virology  / Antiviral chemotherapy

Education

  • Fukushima Medical University

    1980.4 - 1984.3

    　 More details

    Country： Japan

  • Fukushima Medical University

    1974.4 - 1980.3

    　 More details

    Country： Japan

Research History

  • Kagoshima University   Division of Infection Control Research, Center for Advanced Science Research and Promotion   Professor

    2023.4

  • Kagoshima University   President, Executive Director

    2019.4 - 2023.3

  • Kagoshima University   Research Field in Integrated Studies, Integrated Arts and Sciences Area ?   Professor

    2019.4 - 2020.3

Professional Memberships

  • 米国微生物学会（American Society for Microbiology）

  • 日本エイズ学会

  • 日本ウイルス学会

  • 日本抗ウイルス療法学会

  • 国際抗ウイルス学会（International Society for Antiviral Research）

Committee Memberships

  • 日本エイズ学会   評議員  

       

    　 More details

    Committee type：Academic society

  • 日本ウイルス学会   評議員  

       

    　 More details

    Committee type：Academic society

Studying abroad experiences

  • 1986.8 - 1989.3   ルーバン・カトリック大学（Katholike Universiteit Leuven）   博士研究員

 

Papers

  • Taiki Homma, Mika Okamoto, Ryohto Koharazawa, Mayu Hayakawa, Taiki Fushimi, Chisato Tode, Yoshihisa Hirota, Naomi Osakabe, Masanori Baba, Yoshitomo Suhara .  Exploring Novel Vitamin K Derivatives with Anti-SARS-CoV-2 Activity. .  ACS omega8 ( 45 ) 42248 - 42263   2023.11Reviewed International journal

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    From our compound library of vitamin K derivatives, we found that some compounds exhibited anti-SARS-CoV-2 activity in VeroE6/TMPRSS2 cells. The common structure of these compounds was menaquinone-2 (MK-2) with either the m-methylphenyl or the 1-naphthyl group introduced at the end of the side chain. Therefore, new vitamin K derivatives having more potent anti-SARS-CoV-2 activity were explored by introducing various functional groups at the ω-position of the side chain. MK-2 derivatives with a purine moiety showed the most potent antiviral activity among the derivatives. We also found that their mechanism of action was the inhibition of RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2. The chemical structures of our compounds were completely different from those of nucleic acid derivatives such as remdesivir and molnupiravir, clinically approved RdRp inhibitors for COVID-19 treatment, suggesting that our compounds may be effective against viruses resistant to these nucleic acid derivatives.

    DOI： 10.1021/acsomega.3c04175

    Scopus

    PubMed

  • Masanori Baba, Mika Okamoto, Masaaki Toyama, Norikazu Sakakibara, Masayuki Shimojima, Masayuki Saijo, Takuro Niwa, Yoshiki Yagi .  Amodiaquine derivatives as inhibitors of severe fever with thrombocytopenia syndrome virus (SFTSV) replication. .  Antiviral research210   105479 - 105479   2023.2International journal

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne viral infection caused by a bandavirus in the family of Phenuiviridae, commonly known as SFTS virus (SFTSV). We have previously isolated SFTSV from blood samples of SFTS patients and established an antiviral assay system to identify selective inhibitors of SFTSV in vitro. Using the assay system, the antimalarial agent amodiaquine was identified as a selective inhibitor of SFTSV replication. However, due to its insufficient antiviral activity, 98 amodiaquine derivatives were newly synthesized and examined for their anti-SFTSV activity. Among the derivatives, some compounds showed selective inhibitory effect on SFTSV replication in vitro. The 50% effective concentration (EC50) and cytotoxic concentration (CC50) of the most active compound (C-90) were 2.6 ± 0.6 and >50 μM, respectively. This EC50 value was comparable to or slightly better than that of favipiravir (4.1 ± 0.6 μM). On the other hand, pharmacokinetic studies in vivo revealed that C-90 was poor in its oral bioavailability in mice. Therefore, we further designed and synthesized derivatives and obtained 2 compounds with selective anti-SFTSV activity in vitro and improved pharmacokinetics in vivo.

    DOI： 10.1016/j.antiviral.2022.105479

    Scopus

    PubMed

  • Mika Okamoto, Masaaki Toyama, Masanori Baba .  The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. .  Antiviral research182   104902 - 104902   2020.7Reviewed

    　More details

    Cenicriviroc (CVC) is a small-molecule chemokine receptor antagonist with highly potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity through antagonizing C-C chemokine receptor type 5 (CCR5) as a coreceptor of HIV-1. CVC also strongly antagonizes C-C chemokine receptor type 2b (CCR2b), thereby it has potent anti-inflammatory and immunomodulatory effects. CVC is currently under clinical trials in the patients for treatment of nonalcoholic steatohepatitis, in which immune cell activation and dysregulation of proinflammatory cytokines play an important role in its pathogenesis. In this study, CVC was examined for its inhibitory effect on the replication of SARS-CoV-2, the causative agent of COVID-19, in cell cultures and found to be a selective inhibitor of the virus. The 50% effective concentrations of CVC were 19.0 and 2.9 μM in the assays based on the inhibition of virus-induced cell destruction and viral RNA levels in culture supernatants of the infected cells, respectively. Interestingly, the CCR5-specific antagonist maraviroc did not show any anti-SARS-CoV-2 activity. Although the mechanism of SARS-CoV-2 inhibition by CVC remains to be elucidated, CCR2b does not seem to be its target molecule. Considering the fact that the regulation of excessive immune activation is required to treat COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection.

    DOI： 10.1016/j.antiviral.2020.104902

    Scopus

    PubMed

  • 小原沢 諒人, 岡本 実佳, 本間 大暉, 早川 真由, 廣田 佳久, 馬場 昌範, 須原 義智 .  抗SARS-CoV-2活性を有するビタミンK誘導体の創製 .  ビタミン97 ( 4 ) 228 - 228   2023.4抗SARS-CoV-2活性を有するビタミンK誘導体の創製

    　More details

    Language：Japanese   Publisher：(公社)日本ビタミン学会  

  • Takashi Kajiya, Hayate Sawayama, Eriko Arima, Mika Okamoto, Masanori Baba, Masaaki Toyama, Kosuke Okuya, Makoto Ozawa, Nobuhiko Atsuchi, Junichiro Nishi, Yasuo Suda .  Novel RT-PCR Using Sugar Chain-Immobilized Gold-Nanoparticles Correlates Patients’ Symptoms: The Follow-Up Study of COVID-19 Hospitalized Patients .  Viruses14 ( 11 ) 2577 - 2577   2022.11Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：MDPI AG  

    Background: The transmissible capacity and toxicity of SARS-CoV-2 variants are continually changing. We report here the follow-up study of hospitalized COVID-19 patients from 2020 to 2022. It is known that the PCR diagnosis for hospitalized patients sometimes causes confusion because of the incompatibility between their diagnosis and symptoms. We applied our sugar chain-immobilized gold-nanoparticles for the extraction and partial purification of RNA from specimens for quantitative RT-PCR assay and evaluated whether the results correlate with patients’ symptoms. Methods and Results: Saliva specimens were taken from hospitalized patients with mild or moderate symptoms every early morning. At the time of RT-PCR diagnosis, two methods for the extraction and partial purification of RNA from the specimen were performed: a commonly used Boom (Qiagen) method and our original sugar chain-immobilized gold nanoparticle (SGNP) method. For symptoms, body temperature and oxygen saturation (SpO2) of patients were monitored every 4 h. Conclusions: It was clear that patients infected with the Delta variant needed more time to recover than those with the Omicron variant, and that the SGNP method showed more realistic correlation with the symptoms of patients compared with the common Qiagen method.

    DOI： 10.3390/v14112577

    Scopus

    PubMed

  • Masaaki Toyama, Koichi Watashi, Masanori Ikeda, Atsuya Yamashita, Mika Okamoto, Kohji Moriishi, Masamichi Muramatsu, Takaji Wakita, Ashoke Sharon, Masanori Baba .  Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action .  Antimicrobial Agents and Chemotherapy66 ( 6 ) e0207321   2022.6

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：American Society for Microbiology  

    Novel neplanocin A derivatives have been identified as potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro . These include (1S,2R,5R)-5-(5-bromo-4-methyl-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol (AR-II-04-26) and (1S,2R,5R)-5-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-(hydroxylmethyl)cyclopent-3-ene-1,2-diol (MK-III-02-03).

    DOI： 10.1128/aac.02073-21

    Scopus

    PubMed

  • 本間 大暉, 岡本 実佳, 馬場 昌範, 須原 義智 .  抗ウイルス活性を有する新規ビタミン誘導体の研究 .  ビタミン96 ( 4 ) 189 - 189   2022.4抗ウイルス活性を有する新規ビタミン誘導体の研究

    　More details

    Language：Japanese   Publisher：(公社)日本ビタミン学会  

  • Masami Ukawa, Rikito Endo, Haruya Yagi, Takumi Tomono, Kohei Miyata, Koichi Shigeno, Etsuo Tobita, Tomofumi Uto, Masanori Baba, Shinji Sakuma .  Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms .  International Journal of Pharmaceutics613   121376 - 121376   2022.2International journal

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    We have developed an aggregate of D-octaarginine immobilized at multiple points on a co-polymer of N-vinylacetamide and acrylic acid. Previous studies revealed that immunoglobulin G and A were induced when mice were inoculated with influenza virus antigens under coadministration with the D-octaarginine-immobilized polymers as a mucosal vaccine adjuvant. Infection experiments demonstrated that mice vaccinated with a mixture of inactivated influenza viruses and the polymers were protected from infection with mouse-adapted infectious viruses. In the present study, we investigated the mechanism on antigen delivery under mucosal vaccination using the polymers. Two-hour retention of fluorescein-labeled ovalbumin (F-OVA) on the nasal mucosa was observed when applied with the polymers; nevertheless F-OVA was eliminated less than 10 min under polymer-free conditions. F-OVA mixed with the polymers was vigorously taken up into murine dendritic cells. Electrophoresis and dynamic light scattering analysis indicated that OVA interacted with the polymers. The uptake of F-OVA was hardly ever inhibited by the addition of an excess amount of intact OVA. The results suggested that viral antigens were accumulated on the mucosa and delivered into dendritic cells under basolateral membranes via dendrites extending to the mucosal surface and/or subsequent to their permeation through epithelial cells, when they were coadministered with D-octaarginine-immobilized polymers.

    DOI： 10.1016/j.ijpharm.2021.121376

    Scopus

    PubMed

  • Mika Okamoto, Hideto Chono, Akemi Hidaka, Masaaki Toyama, Junichi Mineno, Masanori Baba .  Induction of E. coli-derived endonuclease MazF suppresses HIV-1 production and causes apoptosis in latently infected cells. .  Biochemical and biophysical research communications530 ( 3 ) 597 - 602   2020.9Reviewed

    　More details

    The current antiretroviral therapy cannot cure the patients infected with human immunodeficiency virus type 1 (HIV-1) due to the existence of latently infected cells capable of virus production from harboring proviral DNA. MazF is an ACA nucleotide sequence-specific endoribonuclease derived from Escherichia coli. The conditional expression of MazF by binding of HIV-1 Tat to the promoter region of a MazF-expression vector has previously been shown to selectively inhibit HIV-1 replication in acutely infected cells. The expression of MazF significantly suppressed tumor necrosis factor (TNF)-α-induced HIV-1 production and viral RNA expression in the HIV-1 latently infected cell line OM-10.1 transduced with the MazF-expression vector (OM-10.1/MFR). Moreover, the viability of OM-10.1/MFR cells decreased with increasing concentrations of TNF-α, whereas such decrease was not observed for HL-60 cells transduced with the MazF-expression vector (HL-60/MFR), the uninfected parental cell line of OM-10.1. TNF-α increased the expression of cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase in OM-10.1/MFR cells, indicating that the cell death was caused by the induction of apoptosis. TNF-α-induced expression of MazF mRNA was detected in OM-10.1/MFR but not HL-60/MFR cells, suggesting that TNF-α-induced apoptosis of latently infected cells was due to the expression of MazF. Thus, the anti-HIV-1 gene therapy using the MazF-expression vector may have potential for the cure of HIV-1 infection in combination with suitable latency reversing agents through reducing the size of latently infected cells without viral reactivation.

    DOI： 10.1016/j.bbrc.2020.07.103

    Scopus

    PubMed

  • Riri Yokota, Shun Hashimoto, Ikuko Watanabe, Satoshi Kishimoto, Masaaki Toyama, Mika Okamoto, Makoto Yoshimitsu, Kenji Ishitsuka, Yuji Ito, Masanori Baba .  Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). .  Anticancer research40 ( 8 ) 4471 - 4479   2020.8Reviewed

    　More details

    BACKGROUND/AIM: Adult T-cell leukemia (ATL) is a hematological malignancy caused by infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity. MATERIALS AND METHODS: In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay. RESULTS: The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting other cells. CONCLUSION: The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL.

    DOI： 10.21873/anticanres.14452

    Scopus

    PubMed

  • Ramakrishnamraju Samunuri, Masaaki Toyama, Renuka Sivasankar Pallaka, Seshubabu Neeladri, Ashok Kumar Jha, Masanori Baba, Chandralata Bal .  Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin .  RSC Medicinal Chemistry11 ( 5 ) 597 - 601   2020.5Reviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    © The Royal Society of Chemistry 2020. Modified carbocyclic nucleosides (4a-g) constituting 7-deazapurine, 4′-methyl, exocyclic double bond and 2′,3′-hydroxy were synthesized. NOE and X-ray studies of4cconfirmed the α-configuration of 4′-methyl. The anti-HBV assay demonstrated4e(IC50= 3.4 μM) without notable cytotoxicity (CC50= 87.5 μM) as a promising lead for future exploration.

    DOI： 10.1039/d0md00059k

    Scopus

    PubMed

  • Yoshitaka Furukawa, Heiichiro Hamada, Kazuto Kamikawaji, Taiji Unoki, Hiromasa Inoue, Yukie Tashiro, Mika Okamoto, Masanori Baba, Teruto Hashiguchi .  Successful treatment of an AIDS patient with prolonged Mycobacterium avium bacteremia, high HIV RNA, HBV infection, Kaposi's sarcoma and cytomegalovirus retinitis. .  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy26 ( 2 ) 279 - 281   2020.2Invited Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We report an AIDS patient with a high HIV RNA copy number in the plasma who was successfully treated for prolonged Mycobacterium avium bacteremia and other complications. An HIV-infected patient with high fever, anemia, high alkaline phosphatase, cystic lung lesions, hepatitis B virus infection and Kaposi's sarcoma was referred to our hospital. PCR of the blood revealed Mycobacterium avium bacteremia and the time to blood culture positivity was 8 days. The HIV-1 RNA copy number in the plasma was more than ten million copies/ml and the CD4-positive T cell count was 21 cells/μL. Although the high fever resolved five days after therapy for Mycobacterium avium was started, the fever recurred just before starting anti-retroviral therapy (ART) including dolutegravir. The patient experienced repeated but self-limiting bouts of severe inflammation. Mycobacteremia was intermittently detected up to 79 days, suggesting that the recurrent episodes of inflammation were due to the intermittent dissemination of mycobacteria, and that persistent treatment is needed. Five months after the beginning of ART, the HIV-1 RNA copy number in the plasma was still 28,000 copies/ml. An HIV drug-resistance test revealed sensitivity to all anti-retroviral drugs. Eleven months after the initiation of ART, the HIV RNA copy number in the plasma decreased to 45 copies/mL and the CD4-positive T cell count recovered to 205 cells/μL. Our case also suggests that dolutegravir can be effective in cases with prolonged high levels of HIV RNA. Our findings emphasize that prompt diagnosis and persistent therapy for mycobacterial infection are important for successful treatment.

    DOI： 10.1016/j.jiac.2019.08.012

    Scopus

    PubMed

  • Sohei Tanishita, Masami Ukawa, Takumi Tomono, Yuki Yoshida, Takumi Tsujioka, Kohei Miyata, Etsuo Tobita, Tomofumi Uto, Masanori Baba, Shinji Sakuma .  Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses. .  Bioconjugate chemistry30 ( 12 ) 3028 - 3037   2019.12Invited Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Mucosal vaccination, which secretion of immunoglobulin A (IgA) on the mucosa is accompanied by induction of immunoglobulin G (IgG) in the blood, is one of the most effective ways to circumvent influenza epidemics caused by incorrect prediction of epidemic viral strains or viral mutation. Secreted IgA is expected to prevent hosts from being infected with heterologous viruses because this antibody cross-reacts to strains other than those used for immunization. Our previous mouse experiments revealed that intranasal IgA with cross-reactivity was induced through nasal inoculation with inactivated whole viral particles of the H1N1 A/New Caledonia/20/99 IVR116 (NCL) strain in the presence of hyaluronic acid modified with tetraglycine-l-octaarginine. In the present study, heterologous influenza virus challenge was performed to validate a potential of the hyaluronic acid derivative as a mucosal adjuvant with cross-protective abilities. Serious weight loss was observed when mice were nasally inoculated with inactivated NCL viruses alone and subsequently exposed to mouse-adapted infectious viruses of the H1N1 A/Puerto Rico/8/34 (PR8) strain. The symptom associated with virus infection was hardly ever observed for mice inoculated with a mixture of the viral antigens and tetraglycine-l-octaarginine-linked hyaluronic acid, presumably due to high induction of IgG and IgA capable of cross-reacting to PR8 viruses. Less proliferation of PR8 viruses in those mice was also supported by an insignificant elevation of antibody levels through virus exposure. Our polysaccharide derivative enabled hosts to acquire adaptive immunity with cross-protective abilities against heterologous virus infection.

    DOI： 10.1021/acs.bioconjchem.9b00644

    Scopus

    PubMed

  • Masaaki Toyama, Norikazu Sakakibara, Midori Takeda, Mika Okamoto, Koichi Watashi, Takaji Wakita, Masaya Sugiyama, Masashi Mizokami, Masanori Ikeda, Masanori Baba .  Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. .  Virus research271   197677 - 197677   2019.10Invited Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Chronic hepatitis B virus (HBV) infection is currently treated with nucleoside/nucleotides analogs. They are potent inhibitors of HBV DNA polymerase, which also functions as reverse transcriptase. Although nucleoside/nucleotide analogs efficiently suppress HBV replication in liver cells, they cannot eradicate HBV DNA from liver cells and cure the disease. Therefore, it is still mandatory to identify and develop effective inhibitors that target a step other than reverse transcription in the viral replication cycle. HBV capsid assembly is a critical step for viral replication and an attractive target for inhibition of HBV replication. We conducted in silico screening of compounds expected to bind to the HBV capsid dimer-dimer interaction site. The selected compounds were further examined for their anti-HBV activity in vitro. Among the test compounds, novel pyrimidotriazine derivatives were found to be selective inhibitors of HBV replication in HepG2.2.15.7 cells. Among the compounds, 2-[(2,3-dichlorophenyl)amino]-4-(4-tert-butylphenyl)-8-methyl-4H,9H-pyrimido[1,2-a][1,3,5]triazin-6-one was the most active against HBV replication. Studies on its mechanism of action revealed that the compound interfered with HBV capsid assembly determined by a cell-free capsid assembly system. Thus, the pyrimidotriazine derivatives are considered to be potential leads for novel HBV capsid assembly inhibitors.

    DOI： 10.1016/j.virusres.2019.197677

    Scopus

    PubMed

  • Masami Ukawa, Sohei Tanishita, Haruya Yagi, Yuki Yoshida, Takumi Tomono, Koichi Shigeno, Etsuo Tobita, Tomofumi Uto, Masanori Baba, Shinji Sakuma .  Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination. .  Molecular pharmaceutics16 ( 3 ) 1105 - 1118   2019.3Invited Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We have been investigating the potential use of polymers modified with cell-penetrating peptides as an adjuvant for mucosal vaccination and have already developed nondegradable poly( N-vinylacetamide- co-acrylic acid) (PNVA- co-AA) with which d-octaarginine, a typical cell-penetrating peptide, was grafted. Our previous murine infection experiments demonstrated that immunoglobulin G (IgG) and immunoglobulin A (IgA) were induced in systemic circulation and secreted on nasal mucosa, respectively, through 4-time nasal inoculations with a mixture of influenza viral antigens and d-octaarginine-linked PNVA- co-AA at 7-day intervals, and that immunized mice were perfectly protected from homologous virus infection. In the present study, we designed novel biodegradable polymers bearing cell-penetrating peptides from a perspective of clinical application. Hyaluronic acid whose glucuronic acid was modified with tetraglycine-l-octaarginine at a monosaccharide unit ratio of 30% was successfully developed. The hyaluronic acid derivative exhibited adjuvant activities identical to PNVA- co-AA bearing either d-octaarginine or tetraglycine-d-octaarginine under the above-mentioned inoculation schedule. We further found that there was no difference in humoral immunity between the 4-time inoculations at 7-day intervals and the 2-time inoculations at 28-day intervals. Intranasal IgA induced through the latter schedule with a smaller number of inoculations, which is clinically practical, exhibited cross-reactivity beyond the subtype of viral strains. In vitro toxicity studies demonstrated that the hyaluronic acid derivative was much less toxic than the corresponding PNVA- co-AA derivatives, and that both the polymers and their metabolites did not exhibit genotoxicity. Our results suggested that tetraglycine-l-octaarginine-linked hyaluronic acid would be a clinically valuable and safe adjuvant for mucosal vaccination.

    DOI： 10.1021/acs.molpharmaceut.8b01110

    Scopus

    PubMed

  • Okamoto M, Hidaka A, Toyama M, Baba M .  Galectin-3 is involved in HIV-1 expression through NF-κB activation and associated with Tat in latently infected cells .  Virus Research260   86 - 93   2019.1Galectin-3 is involved in HIV-1 expression through NF-κB activation and associated with Tat in latently infected cellsReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.virusres.2018.11.012

  • Hiroki Kumamoto, Shuhei Imoto, Masayuki Amano, Nobuyo Kuwata-Higashi, Masanori Baba, Hiroaki Mitsuya, Yuki Odanaka, Satoko Shimbara Matsubayashi, Hiromichi Tanaka, Kazuhiro Haraguchi .  Synthesis, Anti-HBV, and Anti-HIV Activities of 3'-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines. .  ACS medicinal chemistry letters9 ( 12 ) 1211 - 1216   2018.12Invited Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Synthesis of 3'-halogeno analogues (5a-d) of 9-[c-4,t-5-bis(hydroxymethyl)-cyclopent-2-en-r-1-yl]-9H-adenine (BCA, 3) was accomplished by means of dual utilization of the vinyl sulfone functional moieties in both 10 and 16 utilizing a SN2' conjugate-addition reaction and a sulfur-extrusive stannylation, respectively. Evaluation of the antiviral activities of 5a-d revealed that introduction of a halogeno-substituent into the 3'-position of (-)-BCA diminished its anti-HIV-1 activity but increased the inhibitory activity for the reverse transcriptase of HBV in that the 3'-fluorinated BCA 5d exhibited the highest activity without significant cytotoxicity.

    DOI： 10.1021/acsmedchemlett.8b00374

    Scopus

    PubMed

  • Sakurai Y, Sakakibara N, Toyama M, Baba M, Davey RA .  Novel amodiaquine derivatives potently inhibit Ebola virus infection .  Antiviral Research160   175 - 182   2018.12Novel amodiaquine derivatives potently inhibit Ebola virus infectionReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.antiviral.2018.10.025

  • Development of sugar chain-binding single-chain variable fragment antibody to adult T-cell leukemia cells using glyco-nanotechnology and phage display method .    163 ( 4 ) 281 - 291   2018.4Development of sugar chain-binding single-chain variable fragment antibody to adult T-cell leukemia cells using glyco-nanotechnology and phage display method

  • Effects of the Chemical Structures of Oligoarginines Conjugated to Biocompatible Polymers as a Mucosal Adjuvant on Antibody Induction in Nasal Cavities .    66 ( 4 ) 375 - 381   2018.4Effects of the Chemical Structures of Oligoarginines Conjugated to Biocompatible Polymers as a Mucosal Adjuvant on Antibody Induction in Nasal Cavities

  • Baba M, Toyama M, Sakakibara N, Okamoto M, Arima N, Saijo M .  Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors .  Antiviral Chemistry and Chemotherapy25 ( 3 ) 83 - 89   2017.12Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitorsReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1177/2040206617740303

  • Tomofumi Uto, Takami Akagi, Masaaki Toyama, Mitsuru Akashi, Masanori Baba .  Induction of innate and adaptive immunity with polyion complex nanoparticle adjuvant carrying human immunodeficiency virus type-1 gp120 .  Journal of Biomedical Nanotechnology13 ( 7 ) 848 - 857   2017.7

    　More details

    Copyright © 2017 American Scientific Publishers. The development of safe and effective vaccines against human immunodeficiency virus type 1 (HIV-1) infection is mandatory to suppress the global AIDS pandemic. We have recently created polyion complex (PIC) nanoparticles (NPs) using the anionic polymer poly(γ-glutamic acid) (γ-PGA) and the cationic protein protamine. Both materials are biodegradable. HIV-1 gp120-carrying PIC NPs (gp120-PIC NPs) were prepared by mixing γ-PGA-graft-L-phenylalanine ethylester polymer with protamine containing gp120 antigen in phosphate-buffered saline, and their effect on the induction of innate and adaptive immune responses was examined in mice. gp120-PIC NPs were efficiently taken up into dendritic cells (DCs). PIC NPs upregulated surface costimulatory molecule expression and cytokine production through the mitogenactivated protein kinase-mediated nuclear factor κB signaling pathway in DCs. The immunization of mice with gp120-PIC NPs resulted in robust induction of antigen-specific CD8+ T cells as well as IgG antibodies. In contrast, such induction was not observed, when mice were immunized with gp120 alone or gp120 plus Alum-base adjuvant or incomplete Freund's adjuvant. Furthermore, PIC NPs could induce antigen-specific effector and central memory CD8+ T cells. These results suggest that PIC NPs have potential as an effective vaccine adjuvant against various infectious diseases including HIV-1/AIDS.

    DOI： 10.1166/jbn.2017.2399

    Scopus

  • Oyero OG, Toyama M, Mitsuhiro N, Onifade AA, Hidaka A, Okamoto M, Baba M .  Selective inhibition of hepatitis C virus replication by Alpha-zam, a Nigella sativa seed formulation .  African Journal of Traditional, Complementary and Alternative Medicines13 ( 6 ) 144 - 148   2016.9Selective inhibition of hepatitis C virus replication by Alpha-zam, a Nigella sativa seed formulationReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Ito W, Toyama M, Okamoto M, Ikeda M, Watashi K, Wakita T, Hashimoto Y, Baba M .  Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative .  Antiviral Chemistry and Chemotherapy24 ( 5-6 ) 148 - 154   2016.8Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivativeReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Uto T, Toyama M, Yoshinaga K, Baba M .  Cepharanthine induces apoptosis through the mitochondria/caspase pathway in murine dendritic cells .  Immunopharmacology and Immunotoxicology38 ( 3 ) 238 - 243   2016.1Cepharanthine induces apoptosis through the mitochondria/caspase pathway in murine dendritic cellsReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3109/08923973.2016

  • Okamoto M, Hidaka A, Toyama M, Hosoya T, Yamamoto M, Hagiwara M, Baba M .  Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039 .  Antiviral Research123   1 - 4   2015.11Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039Reviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Uto T, Akagi T, Akashi M, Baba M .  Induction of potent adaptive immunity by the novel polyion complex nanoparticles .  Clinical Vaccine Immunology22 ( 5 ) 578 - 585   2015.5Induction of potent adaptive immunity by the novel polyion complex nanoparticlesReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Sakakibara N, Balboni G, Congiu C, Onnis V, Demizu Y, Misawa T, Kurihara M, Kato Y, Maruyama T, Toyama M, Okamoto M, Baba M .  Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivatives .  Antiviral Chemistry and Chemotherapy24 ( 2 ) 62 - 71   2015.4Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivativesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. Toyama, H. Aoyama, R. Mukai, M. Nakamura, K. Yoshimura, M. Okamoto, T. Ohshima, Y. Hashimoto, Masanori Baba .  A novel tetramethylnaphthalene derivative selectively inhibits adult T-cell leukemia (ATL) cells in vitro .  Anticancer Research34 ( 4 ) 1771 - 1778   2014.4A novel tetramethylnaphthalene derivative selectively inhibits adult T-cell leukemia (ATL) cells in vitroReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • 馬場昌範 .  エイズウイルス薬に関する研究の最前線 .  鹿児島大学医学部医師会報 ( 33 ) 48 - 49   2013.12エイズウイルス薬に関する研究の最前線

    　More details

    Language：Japanese   Publishing type：Research paper (other academic)  

  • T. Hamasaki, M. Okamoto, Masanori Baba .  Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interaction .  Antimicrobial Agents and Chemotherapy57 ( 3 ) 1323 - 1331   2013.5Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interactionReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. Okamoto, H. Chono, Y. Kawano, N. Saito, H. Tsuda, K. Inoue, I. Kato, J. Mineno, Masanori Baba .  Sustained inhibition of HIV-1 replication by conditional expression of the E. coli-derived endoribonuclease MazF in CD4+ T cells .  Human Gene Therapy Methods24 ( 2 ) 94 - 103   2013.4Sustained inhibition of HIV-1 replication by conditional expression of the E. coli-derived endoribonuclease MazF in CD4+ T cellsReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Uto, M. Toyama, Y. Nishi, T. Akagi, F. Shima, M. Akashi, Masanori Baba .  Uptake of biodegradable poly(γ-glutamic acid) nanoparticles and antigen presentation by dendritic cells in vivo .  Results in Immunology3 ( 1 ) 1 - 9   2013.1Uptake of biodegradable poly(γ-glutamic acid) nanoparticles and antigen presentation by dendritic cells in vivoReviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • M. Toyama, T. Hamasaki, T. Uto, H. Aoyama, M. Okamoto, Y. Hashimoto, Masanori Baba .  Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivative .  Anticancer Research32 ( 7 ) 2639 - 2645   2012.7Synergistic inhibition of HTLV-1-infected cell proliferation by combination of cepharanthine and a tetramethylnaphthalene derivativeReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • P. Ordonez, T. Hamasaki, Y. Isono, N. Sakakibara, M. Ikejiri, T. Maruyama, Masanori Baba .  Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives .  Antimicrobial Agents and Chemotherapy56 ( 5 ) 2581 - 2589   2012.5Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivativesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M.T. Salim, H. Aoyama, K. Sugita, K. Watashi, T. Wakita, T. Hamasaki, M. Okamoto, Y. Urata, Y. Hashimoto, Masanori Baba .  Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives .  Biochemical and Biophysical Research Communications415 ( 4 ) 714 - 718   2011.12Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivativesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Uto, Y. Nishi, M. Toyama, K. Yoshinaga, Masanori Baba .  Inhibitory effect of cepharanthine on dendritic cell activation and function .  International Immunopharmacology11 ( 11 ) 1932 - 1938   2011.11Inhibitory effect of cepharanthine on dendritic cell activation and functionReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Uto, T. Akagi, M. Toyama, Y. Nishi, F. Shima, M. Akashi, Masanori Baba .  Comparable activity of biodegradable nanoparticles with aluminum adjubvants: antigen uptake by dendritic cells and induction of immune response in mice .  Immunology Letters140 ( 42006 ) 35 - 43   2011.10Comparable activity of biodegradable nanoparticles with aluminum adjubvants: antigen uptake by dendritic cells and induction of immune response in miceReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Uto, T. Akagi, K. Yoshinaga, M. Toyama, M. Akashi, Masanori Baba .  The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway .  Biomaterials32 ( 22 ) 5206 - 5212   2011.8The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathwayReviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • T. Hamasaki, M. Toyama, H. Aoyama, Y. White, M. Okamoto, N. Arima, Y. Hashimoto, Masanori Baba .  Selective inhibition of HTLV-1-infected cell proliferation by a novel tetramethylnaphthalene derivative .  Anticancer Research31 ( 6 ) 2241 - 2247   2011.6Selective inhibition of HTLV-1-infected cell proliferation by a novel tetramethylnaphthalene derivativeReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. T. A. Salim, Y. Goto, T. Hamasaki, M. Okamoto, H. Aoyama, Y. Hashimoto, S. Musiu, J. Paeshuyse, J. Neyts, M. Froeyen, P. Herdewijn, Masanori Baba .  Highly potent and selective inhibition of bovine viral diarrhea virus replication by γ-carboline derivatives .  Antiviral Research88 ( 3 ) 263 - 268   2010.12Highly potent and selective inhibition of bovine viral diarrhea virus replication by γ-carboline derivativesReviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • T. Hamasaki, T. Uto, T. Akagi, M. Akashi, Masanori Baba .  Modulation of gene expression related to Toll-like receptor signaling in dendritic cells by poly(γ-glutamic acid) nanoparticles .  Clinical and Vaccine Immunology17 ( 5 ) 748 - 756   2010.5Modulation of gene expression related to Toll-like receptor signaling in dendritic cells by poly(γ-glutamic acid) nanoparticlesReviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • M. T. A. Salim, M. Okamoto, S. Hosoda, H. Aoyama, Y. Hashimoto, Masanori Baba .  Anti-bovine viral diarrhoea virus activity of novel diphenylmethane derivatives .  Antiviral Chemistry & Chemotherapy20 ( 5 ) 193 - 200   2010.4Anti-bovine viral diarrhoea virus activity of novel diphenylmethane derivativesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. Okamoto, M. Sakai, Y. Goto, M. T. A. Salim, C. Baba, K. Goto, K. Watashi, K. Shimotohno, Masanori Baba .  Anti-bovine viral diarrhea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560 .  Antiviral Chemistry & Chemotherapy20 ( 1 ) 47 - 54   2009.9Anti-bovine viral diarrhea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. Shi, X. Wang, M. Okamoto, S. Takao, Masanori Baba .  Inhibition of porcine endogenous retrovirus (PERV) replication by HIV-1 gene expression inhibitors .  Antiviral Research83 ( 2 ) 201 - 204   2009.8Inhibition of porcine endogenous retrovirus (PERV) replication by HIV-1 gene expression inhibitorsReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Uto, T. Akagi, T. Hamasaki, M. Akashi, Masanori Baba .  Modulation of innate and adaptive immunity by biodegradable nanoparticles .  Immunology Letters125 ( 1 ) 46 - 52   2009.6Modulation of innate and adaptive immunity by biodegradable nanoparticlesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Uto, X. Wang, T. Akagi, R. Zenkyu, M. Akashi, Masanori Baba .  Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles .  Biochemical and Biophysical Research Communications379 ( 2 ) 600 - 604   2009.2Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticlesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Masanori Baba, M. Okamoto, T. Hamasaki, S. Horai, X. Wang, Y. Ito, Y. Suda, N. Arima .  Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying cell lines and adult T-cell leulemia cells .  Journal of Virology82 ( 8 ) 3843 - 3852   2008.4Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying cell lines and adult T-cell leulemia cellsReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • X. Wang, T. Uto, T. Akagi, M. Akashi, Masanori Baba .  Poly(γ-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an anti-AIDS vaccine .  Journal of Medical Virology80 ( 1 ) 11 - 19   2008.1Poly(γ-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an anti-AIDS vaccineReviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • X. Wang, T. Uto, T. Akagi, M. Akashi, Masanori Baba .  Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120 .  Journal of Virology81 ( 18 ) 10009 - 10016   2007.9Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • X. Wang, K. Yamataka, M. Okamoto, S. Ikeda, Masanori Baba .  Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphtalene derivative JTK-101 .  Antivral Chemistry and Chemotherapy18 ( 4 ) 201 - 211   2007.8Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphtalene derivative JTK-101Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. Shi, X. Wang, E. De Clercq, S. Takao, Masanori Baba .  Selective inhibition of porcine endogenous retrovirus (PERV) replication in human cells by acyclic nucleoside phosphonates .  Antimicrobial Agents and Chemotherapy51 ( 7 ) 2600 - 2604   2007.7Selective inhibition of porcine endogenous retrovirus (PERV) replication in human cells by acyclic nucleoside phosphonatesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Uto, X. Wang, K. Sato, M. Haraguchi, T. Akagi, M. Akashi, Masanori Baba .  Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity .  The Journal of Immunology178 ( 5 ) 2979 - 2986   2007.3Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunityReviewed

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Masanori Baba, H. Miyake, X. Wang, M. Okamoto, K. Takashima .  Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652 .  Antimicribial Agents and Chemotherapy51 ( 2 ) 707 - 715   2007.2Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. Okamoto, X. Wang, Masanori Baba .  HIV-1-infected macrophages induce astrogliosis by SDF-1alpha and matrix metalloproteinases .  Biochemical and Biophysical Research Communications336 ( 4 ) 1214 - 1220   2005.11HIV-1-infected macrophages induce astrogliosis by SDF-1alpha and matrix metalloproteinasesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Masanori Baba, K. Takashima, H. Miyake, N. Kanzaki, K. Teshima, X. Wang, M. Shiraishi, Y. Iizawa .  TAK-652 inhibits CCR5-mediated HIV-1 infection in vitro and has favorable pharmacokinetics in humans .  Antimicrobial Agents and Chemotherapy49 ( 11 ) 4584 - 4591   2005.11TAK-652 inhibits CCR5-mediated HIV-1 infection in vitro and has favorable pharmacokinetics in humansReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • T. Nitanda, X. Wang, H. Kumamoto, K. Haraguchi, H. Tanaka, Y.-C. Cheng, Masanori Baba .  Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro .  Antimicrobial Agents and Chemotherapy49 ( 8 ) 3355 - 3360   2005.8Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitroReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • K. Takashima, H. Miyake, N. Kanzaki, Y. Tagawa, X. Wang, Y. Sugihara, Y. Iizawa, Masanori Baba .  Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small molecule CCR5 antagonist .  Antimicrobial Agents and Chemotherapy49 ( 8 ) 3474 - 3482   2005.8Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small molecule CCR5 antagonistReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • M. Kawamura, X. Wang, T. Uto, K. Sato, M. Ueno, M. Akagi, K. Hiraishi, T. Matsuyama, M. Akashi, Masanori Baba .  Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice .  Journal of Medical Virology76 ( 1 ) 7 - 15   2005.5Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in miceReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • X. Wang, T. Uto, K. Sato, K. Ide, T. Akagi, M. Okamoto, T. Kaneko, M. Akashi, Masanori Baba .  Potent activation of antigen-specific T cells by antigen-loaded nanospheres .  Immunology Letters98 ( 1 ) 123 - 130   2005.4Potent activation of antigen-specific T cells by antigen-loaded nanospheresReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • C. Baba, K. Yanagida, T. Kanzaki, Masanori Baba .  CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives .  Antiviral Chemistry & Chemotherapy16 ( 1 ) 397 - 416   2005.2CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivativesReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • K. Yanagida, C. Baba, Masanori Baba .  Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: Synergistic effect of combination with interferon-alpha .  Antiviral Research64 ( 3 ) 195 - 201   2004.12Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: Synergistic effect of combination with interferon-alphaReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • X. Wang, T. Nitanda, M. Shi, M. Okamoto, T. Furukawa, Y. Sugimoto, S. Akiyama, Masanori Baba .  Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein .  Biochemical Pharmacology68 ( 7 ) 1363 - 1370   2004.10Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance proteinReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

▼display all

Books

  • ウイルス病の治療

    馬場昌範（ Role： Sole author）

    標準微生物学第12版（医学書院）  2015.4 

    　More details

    Language：Japanese Book type：Scholarly book

  • 侵入阻害薬

    馬場昌範（分担）（ Role： Sole author）

    HIV感染症とAIDS・最新医学社  2014.12 

    　More details

    Language：Japanese Book type：Scholarly book

  • 抗ウイルス薬

    馬場昌範（分担）（ Role： Sole author）

    病原微生物学－基礎と臨床－・東京化学同人  2014.12 

    　More details

    Language：Japanese Book type：Scholarly book

  • 抗ウイルス薬の開発

    馬場昌範（ Role： Joint author）

    新編 ウイルスの今日的意味  2012.9 

    　More details

    Language：Japanese Book type：Scholarly book

  • ウイルス病の治療

    馬場昌範（ Role： Sole author）

    標準微生物学第11版（医学書院）  2012.4 

    　More details

    Language：Japanese Book type：Scholarly book

  • 逆転写酵素阻害薬とプロテアーゼ阻害薬

    馬場昌範（ Role： Sole author）

    HIV感染症とAIDS（最新医学社）  2010.2 

    　More details

    Language：Japanese Book type：Scholarly book

  • ウイルス病の治療

    馬場昌範（ Role： Sole author）

    標準微生物学第１０版（医学書院）  2009.4 

    　More details

    Language：Japanese Book type：Scholarly book

  • 抗ウイルス薬

    馬場昌範（ Role： Sole author）

    ウイルスハンドブック（日本医学館）  2008.6 

    　More details

    Language：Japanese Book type：Scholarly book

  • ウイルス感染症の治療

    馬場昌範（ Role： Sole author）

    シンプル微生物学第４版（南江堂）  2006.5 

    　More details

    Language：Japanese Book type：Scholarly book

  • ウイルス病の治療

    馬場昌範（ Role： Sole author）

    標準微生物学第９版（医学書院）  2005.3 

    　More details

    Language：Japanese Book type：Scholarly book

  • Cellular factors as targets for anti-HIV-1 chemotherapy

    Masanori Baba（ Role： Sole author）

    HIV Chemotherapy: A Critical Review (Horizon Scientific Press/Caister Academic Press)  2005.1 

    　More details

    Language：English Book type：Scholarly book

▼display all

MISC

  • 【これからの抗ウイルス療法】抗ウイルス薬の開発の歴史

    馬場 昌範

    臨床と微生物   45 ( 6 )   675 - 678   2018.11

    　More details

    Publisher：(株)近代出版  

    ヘルペスウイルス感染症に対する治療薬の発見から始まった。抗ウイルス薬の研究と開発の歴史は、ヒト免疫不全ウイルス、インフルエンザウイルス、そして肝炎ウイルスへと、半世紀以上の歳月をかけて、その対象を拡大してきた。その結果、これらのウイルスに対しては、治療効果が高く、副作用の少ない薬剤が開発され、臨床で幅広く使用されている。(著者抄録)

  • 【進化するHIV感染症とAIDSの治療】臨床開発中の抗HIV-1薬

    馬場 昌範

    医学のあゆみ   265 ( 7 )   580 - 584   2018.5

    　More details

    Publisher：医歯薬出版(株)  

    逆転写酵素を阻害するジドブジンの発見により、HIV-1感染症に対する抗ウイルス化学療法が開始されて以来、種々の逆転写酵素阻害薬、プロテアーゼ阻害薬、そしてインテグレース阻害薬がつぎつぎに開発された。その結果、作用機序の異なる薬剤を複数併用する抗レトロウイルス療法(ART)が確立したことで、薬剤耐性ウイルスの出現を抑え、感染者の血中ウイルス量を検出限界以下に維持し続けることが可能となった。さらに最近では、複数の薬剤をまとめた合剤が開発され、服薬が1日1回1錠ですむようになった。このように、ARTはほぼ完成の領域に達した感があるものの、より完全な治療法の確立を求めて新薬の臨床開発がいまもなお積極的に行われている。このなかには、既存の抗HIV-1薬とは作用機序(標的分子)が異なるもの、同じ作用機序ではあるが、より強い薬効と低い毒性を有するもの、そして月に1回程度の投与で十分な効果のある長時間作用型注射薬などがある。とくに長時間作用型注射薬については、抗HIV-1維持療法への適用と、曝露前予防投与への道を開くものとして、大きな期待が寄せられている。(著者抄録)

  • CD70を標的とする抗ATL抗体薬物複合体の開発研究

    横田璃里, 橋本駿, 渡邉いく子, 伊東祐二, 外山政明, 岡本実佳, 馬場昌範

    日本HTLV‐1学会学術集会   5th   78   2018

    　More details

  • 抗ウイルス薬開発の歴史

    馬場昌範

    化学療法の領域   33 ( 1 )   22 - 24   2016.12

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗ウイルス薬の歴史と分類

    馬場昌範

    臨床と微生物   40 ( 1 )   3 - 7   2013.1

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗ウイルス薬研究の歴史と進歩

    馬場昌範

    日本臨床   70 ( 4 )   553 - 557   2012.4

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗ウイルス薬の開発

    馬場昌範

    化学療法の領域   27 ( 9 )   1967 - 1975   2011.9

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • HIV感染症／AIDS治療の進歩の展望－HIVのアキレス腱は他にもあるか－

    馬場昌範

    血液フロンティア（医薬ジャーナル社）   20 ( 12 )   2167 - 2173   2010.12

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • これからの抗HIV薬研究の進むべき方向 Reviewed

    馬場昌範，中田浩智，朝光かおり，駒野 淳，岡本実佳，杉浦 亙

    日本エイズ学会誌   12 ( 2 )   74 - 80   2010.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Entry inhibitors of human immunodeficiency virus Reviewed

    Masanori Baba

    Antiviral Research: Strategies in Antiviral Drug Discovery (ASM Press)   19 ( 32 )   2009.8

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • エイズの現状；社会的影響への考察も含めて

    新薬の開発状況

    Pharma Medica   27 ( 4 )   45 - 49   2008.4

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 新しい抗HIV-1薬開発の展望

    馬場昌範

    化学療法の領域   23 ( 7 )   1102 - 1108   2007.7

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Development of core-corona type polymeric nanoparticles as an anti-HIV-1 vaccine Reviewed

    X. Wang, T. Akagi, M. Akashi, Masanori Baba

    Mini-Reviews in Organic Chemistry   4 ( 1 )   51 - 59   2007.2

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗ウイルス薬(Antiviral agents)

    馬場昌範

    Drug Delivery System   22 ( 1 )   78 - 79   2007.1

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗ウイルス薬

    馬場昌範

    医薬ジャーナル   43 ( S-1 )   90 - 95   2007.1

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Nanotechnology and antiretroviral therapy Reviewed

    Masanori Baba

    Blood   108 ( 8 )   2505 - 2506   2006.10

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Recent advances of CCR5 antagonists Reviewed

    Masanori Baba

    Current Opinion in HIV and AIDS   1 ( 5 )   367 - 372   2006.9

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Recent status of HIV-1 gene expression inhibitors Reviewed

    Masanori Baba

    Antiviral Research   71 ( 2-3 )   301 - 306   2006.9

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 宿主細胞由来の因子を標的とする抗エイズ薬の開発は可能か？

    馬場昌範

    カレントテラピー   24 ( 3 )   321 - 321   2006.3

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 薬剤耐性（ウイルス）

    馬場昌範

    臨床と微生物   33 ( 1 )   94 - 95   2006.1

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • エイズ治療薬の進歩と今後の課題

    馬場昌範

    日本医事新報   ( 4254 )   20 - 24   2005.11

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • A role of breast cancer resistance protein (BCRP/ABCG2) in the cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors Reviewed

    X. Wang, Masanori Baba

    Antiviral Chemistry & Chemotherapy   16 ( 4 )   213 - 216   2005.8

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗ウイルス薬研究の歩み（Advances in antiviral chemotherapy）

    馬場昌範

    ウイルス   55 ( 1 )   69 - 76   2005.6

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • エイズワクチン開発の現況とナノ粒子の応用（Anti-AIDS vaccine development and application of nanospheres）

    馬場昌範, 明石満

    バイオマテリアル   22 ( 6 )   394 - 399   2004.11

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 抗ウイルス薬研究最近の進歩：抗エイズ薬を中心として（Recent progress in anti-HIV-1 research）

    馬場昌範

    ウイルス   54 ( 1 )   59 - 66   2004.6

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Inhibitors of HIV-1 gene expression and transcription Reviewed

    Masanori Baba

    Current Topics in Medicinal Chemistry   4 ( 9 )   871 - 882   2004.5

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

▼display all

Presentations

  • 馬場昌範，岡本実佳   ブタ内在性レトロウイルス（PERV）に対する増殖阻害剤の研究  

    第26回日本異種移植研究会  2024.2 

    　More details

    Event date： 2024.2

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

    Venue：鹿児島市  

  • 馬場昌範，岡本実佳   新型コロナウイルス感染症に対する抗ウイルス薬開発の現状と将来  

    第26回日本神経感染症学会総会・学術集会  2022.10 

    　More details

    Event date： 2022.10

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

    Venue：鹿児島市  

  • 小原沢 諒人, 岡本 実佳, 本間 大暉, 早川 真由, 廣田 佳久, 馬場 昌範, 須原 義智   抗SARS-CoV-2活性を有するビタミンK誘導体の創製  

    ビタミン  2023.4  (公社)日本ビタミン学会

    　More details

    Language：Japanese  

  • 馬場 昌範, 岡本 実佳   新型コロナウイルス感染症に対する抗ウイルス薬開発の現状と将来  

    NEUROINFECTION  2022.10  日本神経感染症学会

    　More details

    Language：Japanese  

  • 八木 晴也, 谷下 宗平, 鵜川 真実, 吉田 祐樹, 飛田 悦男, 宇都 倫史, 馬場 昌範, 佐久間 信至   膜透過ペプチドを固定化したヒアルロン酸誘導体の粘膜投与型ワクチンのアジュバントとしての特性評価  

    日本薬剤学会年会講演要旨集  2018.5  (公社)日本薬剤学会

    　More details

    Language：Japanese  

  • 谷下 宗平, 吉田 祐樹, 辻岡 拓実, 鵜川 真実, 伴野 拓巳, 宮田 康平, 飛田 悦男, 宇都 倫史, 馬場 昌範, 佐久間 信至   膜透過ペプチド固定化ヒアルロン酸を粘膜アジュバントとして含有する経鼻粘膜ワクチンの交差反応性のマウス感染実験による実証  

    日本薬剤学会年会講演要旨集  2019.5  (公社)日本薬剤学会

  • 隅田 泰生, 馬場 昌範, 田島 靖久, 東元 一晃, 坪内 博仁, 西 順一郎, 帖佐 俊行, 加治屋 崇   糖鎖ナノバイオテクノロジーとPCRによる高感度ウイルス検査診断法の開発  

    日本生化学会大会プログラム・講演要旨集  2020.9  (公社)日本生化学会

  • 佐久間 信至, 馬場 昌範   次世代創薬ターゲット"バイオ医薬"の動態を制御するキー分子「細胞膜透過ペプチド」のDDS研究最前線　膜透過ペプチド固定化高分子を用いた粘膜投与型ワクチンの開発  

    日本薬学会年会要旨集  2017.3  (公社)日本薬学会

  • 馬場 昌範   新型コロナウイルス感染症治療薬の現状と将来  

    日本分子腫瘍マーカー研究会プログラム・講演抄録  2020.9  日本分子腫瘍マーカー研究会

  • 谷下 宗平, 八木 晴也, 毛利 浩太, 熊谷 光倫, 宮田 康平, 落合 恭平, 日渡 謙一郎, 滋野 浩一, 飛田 悦男, 宇都 倫史, 馬場 昌範, 佐久間 信至   ヒアルロン酸を支持体とするオクタアルギニン固定化高分子の粘膜投与型ワクチンの抗原キャリアとしての有用性評価  

    日本薬学会年会要旨集  2017.3  (公社)日本薬学会

  • 馬場 昌範   ウイルス感染症とその最新治療薬　新型コロナウイルス感染症からエイズまで  

    Journal of Oral Biosciences Supplement  2020.9  (一社)歯科基礎医学会

  • 馬場 昌範   HIV感染症の早期発見・診療とARTの今後の展望　臨床開発中の抗HIV薬とARTの将来展望  

    感染症学雑誌  2019.3  (一社)日本感染症学会

  • 馬場 昌範   HIV感染症の早期発見・診療とARTの今後の展望(共催:ヴィーブヘルスケア)　臨床開発中の抗HIV薬とARTの将来展望  

    日本化学療法学会雑誌  2019.3  (公社)日本化学療法学会

  • 馬場 昌範   HIVの増殖機構からみた抗エイズ薬の開発  

    臨牀と研究  2020.6  大道学館出版部

  • 馬場 昌範, 岡本 実佳, 青木 伸, 八木 良樹, 外山 政明, 田中 智博, 丹羽 卓朗   MedChemCorona:COVID-19治療薬創製研究の最前線　新型コロナウイルスの複製を阻害する新規化合物の同定と開発(Identification and development of novel compounds inhibitory to SARS-CoV-2 replication)  

    日本薬学会年会要旨集  2021.3  (公社)日本薬学会

    　More details

    Language：English  

  • 馬場 昌範   新型コロナウイルス感染症治療薬開発へのアプローチ  

    日本小児科学会雑誌  2022.2  (公社)日本小児科学会

    　More details

    Language：Japanese  

  • 田中 智博, 横井 健汰, 佐藤 秀哉, 森田 都望恵, 神戸 梓, 吉村 弥生, 岡本 実佳, 外山 政明, 馬場 昌範, 青木 伸   抗マラリア薬アモジアキンをリード化合物とした抗SARS-CoV-2治療薬の創製  

    日本薬学会年会要旨集  2022.3  (公社)日本薬学会

    　More details

    Language：Japanese  

  • 本間 大暉, 岡本 実佳, 馬場 昌範, 須原 義智   抗ウイルス活性を有する新規ビタミン誘導体の研究  

    ビタミン  2022.4  (公社)日本ビタミン学会

    　More details

    Language：Japanese  

  • 馬場 昌範   新型コロナウイルス感染症治療薬開発へのアプローチ  

    日本小児科学会雑誌  2022.2  (公社)日本小児科学会

    　More details

    Language：Japanese  

  • 田中 智博, 横井 健汰, 佐藤 秀哉, 森田 都望恵, 神戸 梓, 吉村 弥生, 岡本 実佳, 外山 政明, 馬場 昌範, 青木 伸   抗マラリア薬アモジアキンをリード化合物とした抗SARS-CoV-2治療薬の創製  

    日本薬学会年会要旨集  2022.3  (公社)日本薬学会

    　More details

    Language：Japanese  

  • 本間 大暉, 岡本 実佳, 馬場 昌範, 須原 義智   抗ウイルス活性を有する新規ビタミン誘導体の研究  

    ビタミン  2022.4  (公社)日本ビタミン学会

    　More details

    Language：Japanese  

  • 金子 達哉, 岡本 実佳, 本間 大暉, 馬場 昌範, 須原 義智   抗SARS-CoV-2活性の増強を目指した新規ビタミンK誘導体の創製  

    ビタミン  2024.4  (公社)日本ビタミン学会

    　More details

    Language：Japanese  

▼display all

Intellectual Property

  • 抗SARS-CoV-2薬

    馬場昌範，岡本実佳，バル チャンドララータ，ミシュラ ウッタム クマル，シャロン アショーカ

    　More details

    Applicant：国立大学法人鹿児島大学

    Application no：特願2024-022040  Date applied：2024.3

  • 抗SARS-CoV-2剤及び化合物の使用

    岡本実佳，馬場昌範，須原義智，本間大暉

    　More details

    Applicant：国立大学法人鹿児島大学，学校法人芝浦工業大学

    Application no：PCT/JP2023/015791  Date applied：2023.4

  • 抗SARS-CoV-2薬

    馬場昌範，岡本実佳，外山政明，青木　伸，田中智博，横井健汰

    　More details

    Applicant：国立大学法人鹿児島大学，学校法人東京理科大学

    Application no：PCT/JP2022/42029  Date applied：2022.11

  • フェナントリジノン誘導体のコリン塩

    浦田泰生，坂内信貴，坂田晃一，馬場昌範，岡本実佳，外山政明

    　More details

    Applicant：オンコリスバイオファーマ株式会社

    Application no：特願2023-081209  Date applied：2023.5

  • 抗SARS-CoV-2薬

    馬場昌範，岡本実佳，外山政明，橋本宏正

    　More details

    Applicant：オンコリスバイオファーマ株式会社

    Application no：PCT/JP2022/ 42332  Date applied：2022.11

Awards

  • 日本エイズ学会賞「シミック賞」

    2014.12   日本エイズ学会   新規抗ＨＩＶ薬の開発とその増殖抑制機構の解明

    馬場 昌範

    　More details

    Award type：Award from Japanese society, conference, symposium, etc.  Country：Japan

  • 国際抗ウイルス学会賞「エリオン賞」

    2013.5   国際抗ウイルス学会 （International Society for Antiviral Research）  

    馬場 昌範

    　More details

    Award type：Award from international society, conference, symposium, etc.  Country：United States

  • 南日本文化賞

    2016.11   南日本新聞社  

    馬場昌範

    　More details

    Award type：Award from publisher, newspaper, foundation, etc.  Country：Japan

Research Projects

  • Antiviral activity of amodiaquine derivatives against SFTSV

    Grant number：17H04084  2017.4 - 2020.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    　 More details

    Grant amount：\16900000 （ Direct Cost: \13000000 、 Indirect Cost：\3900000 ）

  • Investigation on antiviral agents against severe fever with thrombocytopenia syndrome virus (SFTSV)

    Grant number：26460559  2014.4 - 2017.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    BABA MASANORI

    　 More details

    Grant amount：\4940000 （ Direct Cost: \3800000 、 Indirect Cost：\1140000 ）

    SFTS is an emerging tick-borne infectious disease. Its fatality is quite high. However, there are no antiviral agents currently approved for clinical use. We have established a safe and rapid assay system for screening selective inhibitors of SFTSV and tested various compounds in the assay system. When ribavirin and favipiravir were examined for their anti-SFTSV activity, their EC50 values were 40.1 ± 16.3 and 25.0 ± 9.3 μM, respectively. Both compounds have already been reported as selective inhibitors of SFTSV replication in vitro. Furthermore, amodiaquine was found to be effective against SFTSV (EC50 = 19.1 ± 5.1 μM).